We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Siemens Stages Entry as New Diagnostics Powerhouse

By Labmedica staff writers
Posted on 30 Jun 2006
In a bold push to expand the position of its Medical Solutions group in the fast-growing in vitro and molecular diagnostics markets, Siemens AG has agreed to acquire two major diagnostic companies. More...


Following hard on the news of the acquisition of Schering by BayerAG (Leverkusen, Germany), Siemens agreed to acquire the Diagnostics Division of Bayer HealthCare for €4.2 billion. Included in the acquisition, which has been approved by the Bayer supervisory board, is an extensive portfolio of in vitro diagnostics products for evaluating and monitoring the therapy of numerous diseases. Also included is the systems business, which includes hardware, information technology (IT) networking, and comprehensive equipment service. Not included are the Diabetes Care Division of Bayer and the diagnostic imaging business of Schering.

"With this acquisition we are continuing to consistently pursue our strategy of building the industry's first integrated diagnostics company that combines diagnostic imaging, laboratory diagnostics, and clinical information technology under one roof right along the value chain,” explained Erich Reinhardt, CEO and president of Siemens Medical Solutions and member of the managing board of Siemens AG (Munich, Germany). "The aim is to enable trend-setting innovations that improve the quality of health care through early, specific, and efficient diagnostic solutions and thus to address the growing global demand for superior health care solutions.”

Sales of Bayer HealthCare Diagnostics rose in 2005 by 8.4% to $1.75 billion. The division employs more than 5,000 people worldwide. The business units include laboratory testing (Advia Centaur and Centaur CP), Advia Clinical Chemistry, Advia LabCell and WorkCell automation, Advia hematology and Clinitek Atlas systems; near-patient testing, with Rapidpoint, Rapidlab, RapidComm, and Clinitek brands; and molecular testing, with the Trugene and Versant lines of tests and systems.

Only two months earlier, Siemens agreed to acquire Diagnostics Products Corp. (DPC, Los Angeles, USA) for about $1.86 billion. Through its presence in more than 100 countries, DPC offers immunodiagnostic solutions to hospitals, clinics, and laboratories across the globe. Founded in 1971, DPC is the world's leading independent producer of immunodiagnostic products, including the widely accepted Immulite immunoassay systems, as well as assay systems for a wide range of diseases and disorders.

This acquisition was also intended to add to Siemens' existing health care solutions portfolio and further the company's objective to enable early and specific diagnosis and individualized patient therapy. "We are impressed by DPC's track record in developing a global, leading immunodiagnostic business and by the quality of its people,” Reinhardt said, adding, "Together, both companies will be empowered to continue to revolutionize the prevention, diagnosis, treatment, and management of disease.”



Related Links:
BayerAG
Siemens Medical Solutions
Diagnostics Products Corp.

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Gold Member
Pipette Management Software
VIALINK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Brain biomarkers of Alzheimer\'s disease can be detected as early as middle age (Photo courtesy of University of Shutterstock)

Blood-Based Biomarkers Could Detect Alzheimer's as Early as Middle Age

As the global population ages, Alzheimer's disease and other dementing diseases are becoming more prevalent. The disease processes leading to Alzheimer's symptoms can begin years or even decades before... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.